Physician profile
Dirk Harmen Mous
NPI 1538262522
$4,677.41
in general payments reported to CMS, 2019-2025
29 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,092 · 2020: $699 · 2021: $826 · 2022: $624 · 2023: $502 · 2024: $818 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,399 · Education: $36.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,399.40 |
| Education | $36.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $997.96 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $638.00 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $437.95 | 2019-2024 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $310.44 | 2019-2022 | |
| Pfizer INC. | $287.59 | 2019-2024 | |
| Amarin Pharma, INC. | $279.48 | 2019-2021 | |
| Lilly USA, LLC | $278.91 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $253.60 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Bausch Health US, LLC | $158.20 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.67 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $112.54 | 2019-2022 | |
| Dexcom, INC. | $94.86 | 2021-2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $82.18 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $74.83 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.14 | 2021-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $71.95 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $63.24 | 2022 | |
| Merck Sharp & Dohme LLC | $46.40 | 2019-2022 | |
| Hologic Sales and Service, LLC | $40.70 | 2024 | Aptima, Thinprep 2000 Processor |
| Genentech USA, INC. | $36.22 | 2019 | |
| Lundbeck LLC | $29.81 | 2024 | Rexulti |
| Abbott Laboratories | $28.37 | 2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $25.06 | 2024 | Cologuard Collection Kit |
| Philips North America LLC | $22.92 | 2019 | |
| Idorsia Pharmaceuticals US INC | $20.83 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $19.65 | 2021 | |
| Ironwood Pharmaceuticals, INC | $17.01 | 2024 | |
| Avanir Pharmaceuticals, INC. | $15.51 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.39 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dirk Mous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.